Warning! GuruFocus detected
3 Severe warning signs
with BVS.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Bioventus Inc
NAICS : 339112
SIC : 3845
ISIN : US09075A1088
Share Class Description:
BVS: Class ADescription
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 2.27 | |||||
| Debt-to-EBITDA | 8.56 | |||||
| Interest Coverage | 0.67 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.88 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EBITDA Growth Rate | -7.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.7 | |||||
| 3-Year FCF Growth Rate | 155.7 | |||||
| 3-Year Book Growth Rate | -33.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 366.79 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 3.23 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.77 | |||||
| 9-Day RSI | 46.59 | |||||
| 14-Day RSI | 46.58 | |||||
| 3-1 Month Momentum % | -6.19 | |||||
| 6-1 Month Momentum % | -15.53 | |||||
| 12-1 Month Momentum % | 84.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.31 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 180.85 | |||||
| Days Sales Outstanding | 80.85 | |||||
| Days Payable | 42.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.4 | |||||
| Shareholder Yield % | 4.56 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.72 | |||||
| Operating Margin % | 4.54 | |||||
| Net Margin % | -5.85 | |||||
| FCF Margin % | 6.59 | |||||
| ROE % | -21.16 | |||||
| ROA % | -4.31 | |||||
| ROIC % | 3.86 | |||||
| 3-Year ROIIC % | 0.43 | |||||
| ROC (Joel Greenblatt) % | -8.38 | |||||
| ROCE % | -1.79 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 15.05 | |||||
| PE Ratio without NRI | 18.66 | |||||
| PS Ratio | 1.13 | |||||
| PB Ratio | 4.4 | |||||
| Price-to-Free-Cash-Flow | 17.04 | |||||
| Price-to-Operating-Cash-Flow | 16.6 | |||||
| EV-to-EBIT | -94.4 | |||||
| EV-to-EBITDA | 24.87 | |||||
| EV-to-Revenue | 1.7 | |||||
| EV-to-Forward-Revenue | 1.65 | |||||
| EV-to-FCF | 25.83 | |||||
| Price-to-GF-Value | 1.68 | |||||
| Price-to-Projected-FCF | 2.7 | |||||
| Earnings Yield (Greenblatt) % | -1.06 | |||||
| FCF Yield % | 5.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BVS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioventus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 573.28 | ||
| EPS (TTM) ($) | -0.51 | ||
| Beta | 0.8 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.98 | ||
| Volatility % | 92.38 | ||
| 14-Day RSI | 46.58 | ||
| 14-Day ATR ($) | 0.565952 | ||
| 20-Day SMA ($) | 9.845 | ||
| 12-1 Month Momentum % | 84.35 | ||
| 52-Week Range ($) | 3.9 - 14.38 | ||
| Shares Outstanding (Mil) | 66.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioventus Inc Frequently Asked Questions
What is Bioventus Inc(BVS)'s stock price today?
The current price of BVS is $9.89. The 52 week high of BVS is $14.38 and 52 week low is $3.90.
When is next earnings date of Bioventus Inc(BVS)?
The next earnings date of Bioventus Inc(BVS) is 2025-05-07 Est..
Does Bioventus Inc(BVS) pay dividends? If so, how much?
Bioventus Inc(BVS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers